<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-053469</identifier>
<setSpec>0034-9356</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Hyperbaric bupivacaine: a randomized double-blind trial of different doses with or without fentanyl for cesarean section under spinal anesthesia</dc:title>
<dc:description xml:lang="en">OBJECTIVES: To compare the effects of spinal anesthesia        with different doses of hyperbaric bupivacaine with or        without fentanyl in patients undergoing cesarean section.        MATERIAL AND METHODS: Prospective study enrolling 50        ASA1-2 patients undergoing cesarean section, randomized to        5 treatment groups. Groups A, B, C, and D received 15 &amp;#956;g of        fentanyl and group X received no fentanyl. The doses of        hyperbaric bupivacaine given in each group were as follows:        10 mg in Group A, 11 mg in group B, 12 mg in group C, 13        mg in group D, and 14 mg in group X.        RESULTS: Patients in groups A and B had greater        hemodynamic stability than patients in groups C, D, or X        (p&lt;0.05). The incidence of hypotension was 70% in group C        and 80% in groups D and X. The sensory block reached level        T4 in groups D and X and the motor block was complete in        all cases. Postoperative analgesia lasted longer in group D        with a mean (SD) duration of 202 (25) minutes than in group        X with a mean duration of 194 (19) minutes. Assessment on        a visual analog scale was under 3 in all groups except group        A, where 2 patients required administration of propofol.        CONCLUSIONS: Acceptable operative conditions with a        low incidence of hypotension are provided with an 11 mg        dose of hyperbaric bupivacaine</dc:description>
<dc:creator>Abengochea Cotaina, A</dc:creator>
<dc:creator>Bernat García, J</dc:creator>
<dc:creator>Gallego García,  J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">OBJETIVOS: Comparar los efectos de la anestesia subaracnoidea,        en pacientes sometidas a cesárea, empleando distintas        dosis de bupivacaína hiperbara con o sin fentanilo.        MATERIAL Y MÉTODOS: Estudio prospectivo con 50        pacientes ASA I-II sometidas a cesárea y distribuidas        aleatoriamente en cinco grupos. Los grupos A, B, C y D        con 15 &amp;#956;g de fentanilo y el grupo X sin fentanilo. Grupo        A: 10 mg de bupivacaína hiperbara y fentanilo; grupo        B: 11 mg de bupivacaína hiperbara y fentanilo; grupo        C: 12 mg de bupivacaína y fentanilo; gupo D:13 mg de        bupivacaína y fentanilo y grupo X: 14 mg de bupivacaína        hiperbara sin fentanilo.        RESULTADOS: Las pacientes de los grupos A y B presentaron        mayor estabilidad hemodinámica frente a los        pacientes de los grupos C, D y X (p &lt; 0,05). La incidencia        de hipotensión en estos grupos fue del 70% (grupo C)        y del 80% (grupos D y X). En los grupos D y X se alcanzó        un nivel de bloqueo sensitivo T4 y un bloqueo motor        completo en todos los casos. La duración de la analgesia        postoperatoria fue mayor en el grupo D que en el X (202        ± 25 min frente 194 ± 19 min). La EVA intraoperatoria        se mantuvo por debajo de 3 en todos los grupos excepto        en el grupo A, donde en 2 pacientes fue necesaria la        administración de propofol.        CONCLUSIONES: Con dosis de 11 mg de bupivacaína        hiperbara (grupo B) obtenemos unas aceptables condiciones        intraoperatorias, con una baja incidencia de hipotensión</dc:description>
<dc:source>Rev Esp Anestesiol Reanim;54(1): 4-10, ene. 2007. ilus, tab</dc:source>
<dc:identifier>ibc-053469</dc:identifier>
<dc:title xml:lang="es">Estudio aleatorio, doble ciego sobre la utilización de diferentes dosis de bupivacaína hiperbara con o sin fentanilo, en cesáreas con anestesia subaracnoidea</dc:title>
<dc:subject>^d29646</dc:subject>
<dc:subject>^d5574</dc:subject>
<dc:subject>^d13060^s22021</dc:subject>
<dc:subject>^d786^s22045</dc:subject>
<dc:subject>^d4365</dc:subject>
<dc:subject>^d9489^s22020</dc:subject>
<dc:subject>^d9489^s22000</dc:subject>
<dc:subject>^d28037^s22000</dc:subject>
<dc:subject>^d9261^s22021</dc:subject>
<dc:subject>^d2625</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d28037^s22020</dc:subject>
<dc:subject>^d7593^s22057</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d7593^s22054</dc:subject>
<dc:subject>^d790^s22020</dc:subject>
<dc:subject>^d2077^s22079</dc:subject>
<dc:subject>^d790^s22000</dc:subject>
<dc:subject>^d22261</dc:subject>
<dc:subject>^d11747</dc:subject>
<dc:subject>^d9489^s22078</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28037^s22078</dc:subject>
<dc:subject>^d4889^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d4417</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d28387</dc:subject>
<dc:subject>^d7593^s22036</dc:subject>
<dc:subject>^d11729</dc:subject>
<dc:subject>^d7202^s22057</dc:subject>
<dc:subject>^d2077^s22020</dc:subject>
<dc:subject>^d7202^s22036</dc:subject>
<dc:subject>^d2077^s22000</dc:subject>
<dc:subject>^d10333^s22054</dc:subject>
<dc:subject>^d22226</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d790^s22079</dc:subject>
<dc:subject>^d6493^s22021</dc:subject>
<dc:subject>^d7202^s22054</dc:subject>
<dc:type>article</dc:type>
<dc:date>200701</dc:date>
</metadata>
</record>
</ibecs-document>
